Literature DB >> 9049395

Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries.

L J van Doorn1, G E Kleter, L Stuyver, G Maertens, J T Brouwer, S W Schalm, R A Heijtink, W G Quint.   

Abstract

Hepatitis C virus (HCV) isolates from a cohort of 315 patients from the Benelux countries (Belgium, The Netherlands, Luxembourg) were genotyped by means of reverse hybridization Inno-LiPA (line probe assay). Genotypes 1a, 1b, 2a, 2b, 3a, 4a and 5a were detected. From the cohort, isolates representing all types and those showing an aberrant LiPA pattern were further analysed by sequencing parts of the 5' UTR, core (nt 1 to 326; aa residues 1 to 108) and core/E1 (nt 477 to 924; aa residues 159 to 308) regions. Molecular evolutionary analysis of the core and core/E1 regions allowed discrimination between known and additional subtypes, especially within types 2 and 4. The core region is not suitable for classification of new subtypes because of the relatively high level of conservation. The core/E1 region displays a higher level of sequence variation and allows much more distinct discrimination between subtypes. Genotypes 2 and 4 are particularly heterogeneous, with at least 7 and 10 subtypes, respectively. In contrast to previous reports from Europe, HCV isolates from the cohort constituted a highly heterogeneous population of virus variants, especially within genotypes 2 and 4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9049395     DOI: 10.1099/0022-1317-76-7-1871

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Full-genome nucleotide sequence of a hepatitis C virus variant (isolate name VAT96) representing a new subtype within the genotype 2 (arbitrarily 2k).

Authors:  E I Samokhvalov; M Hijikata; R I Gylka; D K Lvov; S Mishiro
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

2.  Genotyping hepatitis C virus isolates from Spain, Brazil, China, and Macau by a simplified PCR method.

Authors:  P V Holland; J M Barrera; M G Ercilla; C F Yoshida; Y Wang; G A de Olim; B Betlach; K Kuramoto; H Okamoto
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

3.  Analysis of hepatitis C virus isolates by serotyping and genotyping.

Authors:  L J van Doorn; B Kleter; I Pike; W Quint
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.

Authors:  Constance N Wose Kinge; Christine Espiritu; Nishi Prabdial-Sing; Nomathamsaqa Patricia Sithebe; Mohsan Saeed; Charles M Rice
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

5.  Viral coat protein peptides with limited sequence homology bind similar domains of alfalfa mosaic virus and tobacco streak virus RNAs.

Authors:  M M Swanson; P Ansel-McKinney; F Houser-Scott; V Yusibov; L S Loesch-Fries; L Gehrke
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods.

Authors:  P M Schneeberger; I Keur; W van der Vliet; K van Hoek; H Boswijk; A M van Loon; W C van Dijk; R H Kauffmann; W Quint; L J van Doorn
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

7.  Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant.

Authors:  Ling Lu; Chunhua Li; Jie Yuan; Teng Lu; Hiroaki Okamoto; Donald G Murphy
Journal:  J Gen Virol       Date:  2012-11-14       Impact factor: 3.891

Review 8.  An overview of HCV molecular biology, replication and immune responses.

Authors:  Usman A Ashfaq; Tariq Javed; Sidra Rehman; Zafar Nawaz; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-04-11       Impact factor: 4.099

Review 9.  The past, present and future of neutralizing antibodies for hepatitis C virus.

Authors:  Jonathan K Ball; Alexander W Tarr; Jane A McKeating
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.